{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:50:08Z","timestamp":1771858208412,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K16797"],"award-info":[{"award-number":["17K16797"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K09673"],"award-info":[{"award-number":["19K09673"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ejphar.2020.173313","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T19:14:42Z","timestamp":1593285282000},"page":"173313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats"],"prefix":"10.1016","volume":"882","author":[{"given":"Shogo","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamaki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youichirou","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173313_bib1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/j.1743-6109.2012.02821.x","article-title":"Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck","volume":"9","author":"Angulo","year":"2012","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.ejphar.2020.173313_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/01.ju.0000064923.29954.7e","article-title":"Chronic ischemia increases prostatic smooth muscle contraction in the rabbit","volume":"170","author":"Azadzoi","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1464-410X.2006.06400.x","article-title":"Atherosclerosis as a risk factor for benign prostatic hyperplasia","volume":"98","author":"Berger","year":"2006","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2020.173313_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.urology.2011.09.039","article-title":"Correlations among cardiovascular risk factors, prostate blood flow, and prostate volume in patients with clinical benign prostatic hyperplasia","volume":"79","author":"Chen","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2020.173313_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2011.03.055","article-title":"The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation","volume":"60","author":"De Nunzio","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1743-6109.2009.01511.x","article-title":"Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract","volume":"7","author":"Fibbi","year":"2010","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.ejphar.2020.173313_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/pros.23759","article-title":"Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model","volume":"79","author":"Fujii","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2020.173313_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","article-title":"Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"70","author":"Gacci","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2012.09.006","article-title":"The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"63","author":"Giuliano","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.1939-4640.2000.tb03276.x","article-title":"Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats","volume":"21","author":"Golomb","year":"2000","journal-title":"J. Androl."},{"key":"10.1016\/j.ejphar.2020.173313_bib11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pros.23658","article-title":"The association between local atherosclerosis of the prostatic artery and benign prostatic enlargement in humans: putative mechanism of chronic ischemia for prostatic enlargement","volume":"78","author":"Haga","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2020.173313_bib12","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/pros.23063","article-title":"Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat","volume":"75","author":"Holmstrom","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2020.173313_bib13","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/sj.bjc.6600296","article-title":"A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs","volume":"86","author":"Hori","year":"2002","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173313_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/luts.12046","article-title":"Men with hypertension are more likely to have severe lower urinary tract symptoms and large prostate volume","volume":"7","author":"Hwang","year":"2015","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"10.1016\/j.ejphar.2020.173313_bib15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0022-5347(05)66595-0","article-title":"Chronic ischemia alters prostate structure and reactivity in rabbits","volume":"165","author":"Kozlowski","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1159\/000496289","article-title":"Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review","volume":"65","author":"Madersbacher","year":"2019","journal-title":"Gerontology"},{"key":"10.1016\/j.ejphar.2020.173313_bib17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1476-5381.2010.00873.x","article-title":"Guidelines for reporting experiments involving animals: the ARRIVE guidelines","volume":"160","author":"McGrath","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173313_bib18","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1111\/j.1743-6109.2011.02416.x","article-title":"Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats","volume":"8","author":"Morelli","year":"2011","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.ejphar.2020.173313_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/iju.14171","article-title":"Effects of silodosin and tadalafil on bladder dysfunction in spontaneously hypertensive rats: possible role of bladder blood flow","volume":"27","author":"Nagao","year":"2020","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11010-011-0936-9","article-title":"Rhos and Rho kinases in the rat prostate: their possible functional roles and distributions","volume":"358","author":"Saito","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2020.173313_bib21","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1038\/srep03822","article-title":"Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH","volume":"4","author":"Saito","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.173313_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJMcp1106637","article-title":"Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms","volume":"367","author":"Sarma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173313_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/aje\/kwp406","article-title":"Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial","volume":"171","author":"Schenk","year":"2010","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.ejphar.2020.173313_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133798","article-title":"Effect of silodosin, an Alpha1A-adrenoceptor antagonist, on ventral prostatic hyperplasia in the spontaneously hypertensive rat","volume":"10","author":"Shimizu","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173313_bib25","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/iju.12501","article-title":"Lower urinary tract symptoms, benign prostatic hyperplasia\/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction?","volume":"21","author":"Shimizu","year":"2014","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12894-019-0525-x","article-title":"A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis","volume":"19","author":"Sugimoto","year":"2019","journal-title":"BMC Urol."},{"key":"10.1016\/j.ejphar.2020.173313_bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0090-4295(02)02167-2","article-title":"Determination of percent area density of epithelial and stromal components in development of prostatic hyperplasia in spontaneously hypertensive rats","volume":"61","author":"Yamashita","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.ejphar.2020.173313_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2015.01.050","article-title":"Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension\/emptying and abdominal aorta clamping\/release","volume":"754","author":"Yoshinaga","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173313_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/pros.22909","article-title":"Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia","volume":"75","author":"Zarifpour","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2020.173313_bib30","article-title":"Upregulation of phosphodiesterase type 5 in the hyperplastic prostate","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci. Rep."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920304052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920304052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:43:34Z","timestamp":1757976214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920304052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":30,"alternative-id":["S0014299920304052"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173313","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173313"}}